Boston Scientific stock (NYSE: BSX) has gained 3% in the five days since its Q4 earnings report last week. Although the company exceeded expectations with both its results and guidance, the modest stock increase may be due to the significant price appreciation ahead of the earnings announcement.
BSX, ENVA and CFR made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on February 10, 2025.
PFIS, BSX, ENVA, NFG and NLY have been added to the Zacks Rank #1 (Strong Buy) List on February 10, 2025.
Does Boston Scientific (BSX) have what it takes to be a top stock pick for momentum investors? Let's find out.
Here is how Boston Scientific (BSX) and Alphatec (ATEC) have performed compared to their sector so far this year.
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Boston Scientific Corporation (NYSE:BSX ) Q4 2024 Earnings Conference Call February 5, 2025 8:00 AM ET Company Participants Jonathan Monson - SVP, IR Michael Mahoney - Chairman and CEO Daniel Brennan - EVP and CFO Kenneth Stein - Chief Medical Officer Conference Call Participants Robbie Marcus - JPMorgan Larry Biegelsen - Wells Fargo Frederick Wise - Stifel Joanne Wuensch - Citibank David Roman - Goldman Sachs Travis Steed - Bank of America Patrick Wood - Morgan Stanley Danielle Antalffy - UBS Michael Polark - Wolfe Research Vijay Kumar - Evercore ISI Pito Chickering - Deutsche Bank Joshua Jennings - TD Cowen Chris Pasquale - Nephron Research Operator Good morning, and welcome to the Boston Scientific Fourth Quarter 2024 Earnings Call. All participants will be listen-only mode.
The headline numbers for Boston Scientific (BSX) give insight into how the company performed in the quarter ended December 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Boston Scientific's fourth-quarter 2024 performance reflects the strength of its core franchises.
Boston Scientific (BSX) came out with quarterly earnings of $0.70 per share, beating the Zacks Consensus Estimate of $0.65 per share. This compares to earnings of $0.55 per share a year ago.
Medical device maker Boston Scientific forecast annual profit above Wall Street estimates on Wednesday, banking on steady demand for its heart devices.
Evaluate the expected performance of Boston Scientific (BSX) for the quarter ended December 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.